GSK’s AS03 pandemic adjuvant technology is already the subject of separate COVID-19 vaccine development collaborations with the University of Queensland in Brisbane, Australia, with Sichuan Clover Biopharmaceuticals Inc., of Chengdu, China, and with Fujian, China-based Xiamen Innovax Biotech Co. Ltd. It comprises alpha-tocopherol, squalene and polysorbate 80, combined in an oil-in-water emulsion, and offers the potential for dose-sparing because of its immune-boosting properties.
